MaxCyte (MXCT) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed MaxCyte (MXCT) over the past year, losing 35.9% versus a loss of 40.0%. Over five years, SERA leads with a -81.4% price change compared with -90.8% for MXCT. MaxCyte is the larger company by market cap ($105.3 million vs $79.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | SERA |
|---|---|---|
| Share price | $1.02 | $2.02 |
| Market cap | $105.27M | $79.69M |
| 1-day change | -1.92% | -2.42% |
| YTD return | -34.19% | -31.53% |
| 1-year return | -40.00% | -35.87% |
| 5-year return | -90.75% | -81.38% |
| EPS (TTM) | $-0.34 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.87 | $3.95 |
| 52-week low | $0.643 | $1.56 |
| Distance from 52-week high | -45.31% | -48.86% |
| Analyst consensus | none | none |
| Avg. price target upside | +302.94% | +172.28% |
| Average volume | 668.82K | 28.38K |
| Shares outstanding | 103.21M | 38.48M |
| Employees | 91 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Healthcare · Medical Devices · 71 employees
MXCT vs SERA FAQ
Which is bigger, MaxCyte or Sera Prognostics?
MaxCyte (MXCT) is larger, with a market capitalization of $105.27M compared with $79.69M for Sera Prognostics (SERA).
Which stock has performed better over the past year, MXCT or SERA?
SERA returned -35.87% over the past 12 months, compared with -40.00% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.